Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 20, 2017 16:05 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Entinostat Data to be Presented at the 2017 American Society of Clinical Oncology Annual Meeting

WALTHAM, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and...
April 04, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors

WALTHAM, Mass., April 04, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
March 29, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Announces Presentations at the 2017 American Association for Cancer Research Annual Meeting

WALTHAM, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
March 02, 2017 16:05 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update

Encore 601 refractory melanoma cohort to proceed to second stage of Phase 2; pre-specified objective response criteria satisfiedEnrollment of the first stage of both NSCLC cohorts completed; decision...
February 27, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences

WALTHAM, Mass., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple...
February 16, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax to Announce Fourth Quarter and Year-end 2016 Financial Results and Host Conference Call and Webcast on March 2, 2017

WALTHAM, Mass., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Syndax (Nasdaq:SNDX) announced today that it will release its fourth quarter 2016 financial results on Thursday, March 2, 2017, after the close of...
February 09, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Appoints Richard P. Shea as Chief Financial Officer

WALTHAM, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
January 31, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Appoints Lisa M. Coussens, Ph.D., to Scientific Advisory Board

WALTHAM, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
January 05, 2017 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Adds Global Pharmaceutical Business Veteran to Board of Directors

WALTHAM, Mass., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the “Company” or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing...
December 14, 2016 07:00 ET | Source: Syndax Pharmaceuticals, Inc.

Syndax Pharmaceuticals Announces Collaboration with the National Cancer Institute to Develop Entinostat and SNDX-6352 for the Treatment of Cancer

WALTHAM, Mass., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and...